Abeona Therapeutics Inc
ABEO
查看详细走势图
4.306USD
-0.024-0.56%
交易中 （美东）报价延迟15分钟
83.17K总市值
3.20市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.56%
5天
-3.24%
1月
-15.91%
6月
-19.22%
今年开始到现在
-18.30%
1年
-13.37%
查看详细走势图
TradingKey Abeona Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Abeona Therapeutics Inc当前公司基本面数据相对非常健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名59/157位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价19.57。中期看，股价处于下降通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Abeona Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Abeona Therapeutics Inc亮点
亮点风险
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
业绩高增长
公司营业收入稳步增长，连续3年增长66.29%
业绩增长期
公司处于发展阶段，最新年度总收入5.82M美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值3.19，处于3年历史高位
机构减仓
最新机构持股36.22M股，环比减少0.03%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值2.76M
活跃度降低
近期活跃度降低，过去20天平均换手率-0.04
分析师目标
根据
6
位分析师
强力买入
评级
19.571
目标均价
+352.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Abeona Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Abeona Therapeutics Inc简介
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
公司代码ABEO
公司Abeona Therapeutics Inc
CEOSeshadri (Vishwas)
网址https://abeonatherapeutics.com/
相关品种
